Prognostic value of glucose transporter 3 expression in hepatocellular carcinoma

Gao,Hengjun; Hao,Yijie; Zhou,Xu; Li,Hongguang; Liu,Fangfeng; Zhu,Huaqiang; Song,Xie; Niu,Zheyu; Ni,Qingqiang; Chen,Min‑Shan; Lu,Jun

doi:10.3892/ol.2019.11191

Prognostic value of glucose transporter 3 expression in hepatocellular carcinoma

Authors:
- Hengjun Gao
- Yijie Hao
- Xu Zhou
- Hongguang Li
- Fangfeng Liu
- Huaqiang Zhu
- Xie Song
- Zheyu Niu
- Qingqiang Ni
- Min‑Shan Chen
- Jun Lu
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China, Department of Hepatobiliary Surgery, Sun Yat‑sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China
Published online on: December 9, 2019 https://doi.org/10.3892/ol.2019.11191
Pages: 691-699
Copyright: © Gao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Determining an effective biomarker for predicting the prognosis of patients with hepatocellular carcinoma (HCC) may improve patient survival rates. The present study aimed to investigate the expression of glucose transporter 3 (GLUT‑3) in HCC and to determine its predictive value for the survival of patients with HCC. Immunohistochemistry was used to detect GLUT‑3 expression in HCC tissues of 275 and 140 patients with HCC from training and validation cohorts, respectively. The association between GLUT‑3 expression and the clinicopathological characteristics of patients with HCC, and between GLUT‑3 expression and patient survival rates were analyzed. The predictive value of GLUT‑3 expression was confirmed using the validation cohort. The results demonstrated that the high GLUT‑3 expression in HCC tissues was significantly associated with elevated α‑fetoprotein level, large tumor size, poor histological differentiation and Tumor‑Node‑Metastasis stages III and IV (P<0.05). In addition, GLUT‑3 high expression was also significantly associated with reduced overall survival of patients with HCC in the training and validation cohorts. In conclusion, the results from the present study suggested that GLUT‑3 may be considered as a potential independent prognostic factor for predicting the survival of patients with HCC.

View Figures

View References

1	Global Burden of Disease Cancer Collaboration, ; Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, Allen C, Alsharif U, Alvis-Guzman N, Amini E, Anderson BO, et al: Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: A systematic analysis for the global burden of disease study. JAMA Oncol. 4:1553–1568. 2018. View Article : Google Scholar : PubMed/NCBI
2	El-Serag HB, Marrero JA, Rudolph L and Reddy KR: Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 134:1752–1763. 2008. View Article : Google Scholar : PubMed/NCBI
3	Sirivatanauksorn Y and Tovikkai C: Comparison of staging systems of hepatocellular carcinoma. HPB Surg. 2011:8182172011. View Article : Google Scholar : PubMed/NCBI
4	Barron CC, Bilan PJ, Tsakiridis T and Tsiani E: Facilitative glucose transporters: Implications for cancer detection, prognosis and treatment. Metabolism. 65:124–139. 2016. View Article : Google Scholar : PubMed/NCBI
5	Ayala FR, Rocha RM, Carvalho KC, Carvalho AL, da Cunha IW, Lourenço SV and Soares FA: GLUT1 and GLUT3 as potential prognostic markers for Oral squamous cell carcinoma. Molecules. 15:2374–2387. 2010. View Article : Google Scholar : PubMed/NCBI
6	Estilo CL, O-charoenrat P, Talbot S, Socci ND, Carlson DL, Ghossein R, Williams T, Yonekawa Y, Ramanathan Y, Boyle JO, et al: Oral tongue cancer gene expression profiling: Identification of novel potential prognosticators by oligonucleotide microarray analysis. BMC Cancer. 9:112009. View Article : Google Scholar : PubMed/NCBI
7	Baer S, Casaubon L, Schwartz MR, Marcogliese A and Younes M: Glut3 expression in biopsy specimens of laryngeal carcinoma is associated with poor survival. Laryngoscope. 112:393–396. 2002. View Article : Google Scholar : PubMed/NCBI
8	Younes M, Brown RW, Stephenson M, Gondo M and Cagle PT: Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer. 80:1046–1051. 1997. View Article : Google Scholar : PubMed/NCBI
9	Conde VR, Oliveira PF, Nunes AR, Rocha CS, Ramalhosa E, Pereira JA, Alves MG and Silva BM: The progression from a lower to a higher invasive stage of bladder cancer is associated with severe alterations in glucose and pyruvate metabolism. Exp Cell Res. 335:91–98. 2015. View Article : Google Scholar : PubMed/NCBI
10	Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC and Williams R: Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 60:646–649. 1973. View Article : Google Scholar : PubMed/NCBI
11	Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A and Roberts LR: A global view of hepatocellular carcinoma: Trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 16:589–604. 2019. View Article : Google Scholar : PubMed/NCBI
12	Hong SS, Kim TK, Sung KB, Kim PN, Ha HK, Kim AY and Lee MG: Extrahepatic spread of hepatocellular carcinoma: A pictorial review. Eur Radiol. 13:874–882. 2003. View Article : Google Scholar : PubMed/NCBI
13	Tabrizian P, Jibara G, Shrager B, Schwartz M and Roayaie S: Recurrence of hepatocellular cancer after resection: Patterns, treatments, and prognosis. Ann Surg. 261:947–955. 2015. View Article : Google Scholar : PubMed/NCBI
14	Chun YH, Kim SU, Park JY, Kim DY, Han KH, Chon CY, Kim BK, Choi GH, Kim KS, Choi JS and Ahn SH: Prognostic value of the 7th edition of the AJCC staging system as a clinical staging system in patients with hepatocellular carcinoma. Eur J Cancer. 47:2568–2575. 2011. View Article : Google Scholar : PubMed/NCBI
15	Cillo U, Vitale A, Grigoletto F, Farinati F, Brolese A, Zanus G, Neri D, Boccagni P, Srsen N, D'Amico F, et al: Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol. 44:723–731. 2006. View Article : Google Scholar : PubMed/NCBI
16	Ma WJ, Wang HY and Teng LS: Correlation analysis of preoperative serum alpha-fetoprotein (AFP) level and prognosis of hepatocellular carcinoma (HCC) after hepatectomy. World J Surg Oncol. 11:2122013. View Article : Google Scholar : PubMed/NCBI
17	Yamashita T, Forgues M, Wang W, Kim JW, Ye Q, Jia H, Budhu A, Zanetti KA, Chen Y, Qin LX, et al: EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res. 68:1451–1461. 2008. View Article : Google Scholar : PubMed/NCBI
18	Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D, Alsinet C, Cornella H, Liberzon A, Kobayashi M, Kumada H, et al: Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology. 140:1501–1512.e2. 2011. View Article : Google Scholar : PubMed/NCBI
19	Jin GZ, Yu WL, Dong H, Zhou WP, Gu YJ, Yu H, Yu H, Lu XY, Xian ZH, Liu YK, et al: SUOX is a promising diagnostic and prognostic biomarker for hepatocellular carcinoma. J Hepatol. 59:510–517. 2013. View Article : Google Scholar : PubMed/NCBI
20	Nault JC, De Reynies A, Villanueva A, Calderaro J, Rebouissou S, Couchy G, Decaens T, Franco D, Imbeaud S, Rousseau F, et al: A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology. 145:176–187. 2013. View Article : Google Scholar : PubMed/NCBI
21	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
22	Gatenby RA and Gillies RJ: Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 4:891–899. 2004. View Article : Google Scholar : PubMed/NCBI
23	Macheda ML, Rogers S and Best JD: Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol. 202:654–662. 2005. View Article : Google Scholar : PubMed/NCBI
24	Krzeslak A, Wojcik-Krowiranda K, Forma E, Jozwiak P, Romanowicz H, Bienkiewicz A and Brys M: Expression of GLUT1 and GLUT3 glucose transporters in endometrial and breast cancers. Pathol Oncol Res. 18:721–728. 2012. View Article : Google Scholar : PubMed/NCBI
25	Ha TK, Her NG, Lee MG, Ryu BK, Lee JH, Han J, Jeong SI, Kang MJ, Kim NH, Kim HJ and Chi SG: Caveolin-1 increases aerobic glycolysis in colorectal cancers by stimulating HMGA1-mediated GLUT3 transcription. Cancer Res. 72:4097–4109. 2012. View Article : Google Scholar : PubMed/NCBI
26	Boado RJ, Black KL and Pardridge WM: Gene expression of GLUT3 and GLUT1 glucose transporters in human brain tumors. Brain Res Mol Brain Res. 27:51–57. 1994. View Article : Google Scholar : PubMed/NCBI
27	Starska K, Forma E, Jozwiak P, Brys M, Lewy-Trenda I, Brzezinska-Blaszczyk E and Krzeslak A: Gene and protein expression of glucose transporter 1 and glucose transporter 3 in human laryngeal cancer-the relationship with regulatory hypoxia-inducible factor-1α expression, tumor invasiveness, and patient prognosis. Tumour Biol. 36:2309–2321. 2015. View Article : Google Scholar : PubMed/NCBI
28	Haber RS, Weinstein SP, O'Boyle E and Morgello S: Tissue distribution of the human GLUT3 glucose transporter. Endocrinology. 132:2538–2543. 1993. View Article : Google Scholar : PubMed/NCBI
29	Maratou E, Dimitriadis G, Kollias A, Boutati E, Lambadiari V, Mitrou P and Raptis SA: Glucose transporter expression on the plasma membrane of resting and activated white blood cells. Eur J Clin Invest. 37:282–290. 2007. View Article : Google Scholar : PubMed/NCBI
30	Lunt SY and Vander Heiden MG: Aerobic glycolysis: Meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol. 27:441–464. 2011. View Article : Google Scholar : PubMed/NCBI
31	Warburg O, Wind F and Negelein E: The metabolism of tumors in the body. J Gen Physiol. 8:519–530. 1927. View Article : Google Scholar : PubMed/NCBI
32	O'Rourke JF, Pugh CW, Bartlett SM and Ratcliffe PJ: Identification of hypoxically inducible mRNAs in HeLa cells using differential-display PCR. Role of hypoxia-inducible factor-1. Eur J Biochem. 241:403–410. 1996. View Article : Google Scholar : PubMed/NCBI
33	Zhang HL, Wang MD, Zhou X, Qin CJ, Fu GB, Tang L, Wu H, Huang S, Zhao LH, Zeng M, et al: Blocking preferential glucose uptake sensitizes liver tumor-initiating cells to glucose restriction and sorafenib treatment. Cancer Lett. 388:1–11. 2017. View Article : Google Scholar : PubMed/NCBI
34	Darnell JE Jr, Kerr IM and Stark GR: Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 264:1415–1421. 1994. View Article : Google Scholar : PubMed/NCBI
35	Zhong Z, Wen Z and Darnell JE Jr: Stat3: A STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science. 264:95–98. 1994. View Article : Google Scholar : PubMed/NCBI
36	Baumann MU, Zamudio S and Illsley NP: Hypoxic upregulation of glucose transporters in BeWo choriocarcinoma cells is mediated by hypoxia-inducible factor-1. Am J Physiol Cell Physiol. 293:C477–C485. 2007. View Article : Google Scholar : PubMed/NCBI